OneOme's RightMed Test
OneOme has launched its RightMed test, a 22-gene pharmacogenomic assay intended to be provided as part of routine clinical care. The company said the test can potentially inform treatment decisions across more than 340 medications. OneOme has also developed a platform that allows users to generate a report to guide prescribing using genotype or sequence data obtained elsewhere.
RightMed will be offered through the company's CLIA-registered laboratory in Minneapolis, which it opened in July. OneOme has also entered the market in Puerto Rico, Cuba, and the Dominican Republic through a partnership with High Profile Laboratory in Guaynabo, Puerto Rico.